Research Study

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Principal Investigator 
Theodore Steiner


Body Locations and Systems 
Clostridium Difficile Infections 
Closed for Recruitment
Study Start/End 
Mar 10, 2016 to Nov 13, 2019
Diamond Health Care Centre
Purpose of Study 

This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension).


Visit for more information.


Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.